Prediction and regulation of 5-FU blood concentration

ABSTRACT: Primary objectives: To determine the percentage of the patients that achieve optimal 5-FU exposure within two dose cycles of 5-FU, which is defined by an AUC target of 5-FU between 20 and 30 mg*h/L or dose limiting toxicity. Primary endpoints: The percentage of the patients that achieve optimal 5-FU exposure within two dose cycles of 5-FU, which is defined by an AUC target of 5-FU between 20 and 30 mg*h/L or dose limiting toxicity.

DISEASE(S): The Clinical Trial Is Conducted In Patients Undergoing Folfox, Folfiri And Folfirinox Chemotherapy. Most Of These Patients Have Colorectal Or Pancreatic Cancer.

PROVIDER: 2539584 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR